Atgam Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Atgam market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to the increasing incidence of autoimmune conditions, the growth of organ transplantation procedures, the expansion of stem cell transplantation, the rise of clinical treatment centers, and the increasing prevalence of chronic diseases.

The projected growth in the forecast period is driven by supportive government policies and initiatives, expanded healthcare infrastructure and funding, a growing geriatric population, a rise in cases of organ failure, and increased consumer spending on personal health. Key trends during the forecast period include clinical applications, technological advancements, the development of new drug formulations, a rise in research and development activities, and a shift toward personalized medicine.

The growth of the atgam market is being driven by a rising rate of organ transplantation. Organ transplantation, the surgical replacement of a diseased or dysfunctional organ with a healthy one from a donor, is increasingly being performed due to factors such as chronic diseases, aging populations, and advances in medical research and funding. Atgam is essential in organ transplantation, as it prevents acute organ rejection by targeting and depleting T-cells, thus reducing immune activity. It is commonly used in combination with other immunosuppressive drugs to enhance graft acceptance and improve transplant outcomes. For example, according to the Organ Procurement and Transplantation Network, a record 46,632 organ transplants were performed in the U.S. in 2023, marking an 8.7% increase from 2022 and a 12.7% increase from 2021. This surge in organ transplants is a major factor driving the growth of the atgam market.

The growth of the atgam market is also being fueled by the increasing geriatric population. The geriatric population, individuals aged 65 and older, often require specialized healthcare and are more susceptible to immune-related complications, especially when undergoing organ transplants or managing autoimmune disorders. With advancements in healthcare, life expectancy has increased, leading to a significant rise in the elderly population globally. Atgam plays a crucial role in these patients by preventing organ rejection and modulating the immune system, enhancing transplant outcomes and improving their quality of life. The World Health Organization projects that by 2030, 1 in 6 people worldwide will be aged 60 years or older, with the global population of individuals aged 60 and above reaching 1.4 billion by 2030 and 2.1 billion by 2050. The growing geriatric population is therefore a key driver for the atgam market.

A significant trend in the atgam market is the increasing focus on labeling supplements, which are documents submitted to regulatory authorities to update a product's labeling in line with current regulations. Labeling supplements can include new indications, safety information, or dosing instructions. For example, in February 2023, Pfizer Inc. submitted a Prior Approval Supplement (PAS) to update the pharmacokinetic (PK) data for Atgam, which is used to treat renal allograft rejection and moderate to severe aplastic anemia. The proposed revisions include PK data from a study in Japanese adults with aplastic anemia, demonstrating how regulatory updates to labeling can contribute to product improvements and competitive advantage in the market.

The key company operating in the atgam market is Pfizer Inc.

North America was the largest region in the atgam market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atgam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the atgam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Atgam is a prescription medication made from antithymocyte globulin (equine), derived from horse serum, and is used to suppress the immune system. It is primarily indicated for treating aplastic anemia and preventing organ transplant rejection by reducing the activity of T lymphocytes, which are crucial immune cells. Atgam works by dampening immune activity, preventing the immune system from attacking transplanted organs or the body's own tissues.

The main clinical indications for atgam include renal transplant rejection and aplastic anemia. It is an intravenous immunosuppressant used short-term to prevent acute renal transplant rejection by suppressing immune system activity. Atgam is distributed through various channels, such as hospital pharmacies and retail pharmacies, and is used by adults and geriatric patients.

The atgam market research report is one of a series of new reports that provides atgam market statistics, including the atgam industry global market size, regional shares, competitors with the atgam market share, detailed atgam market segments, market trends, and opportunities, and any further data you may need to thrive in the atgam industry. This atgam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atgam market consists of sales of the anti-thymocyte globulin (ATG). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.